About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3587412
Allelic
Composition
Cd36tm1Mfe/Cd36tm1Mfe
Genetic
Background
involves: 129S1/Sv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd36tm1Mfe mutation (1 available); any Cd36 mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
N
• glycogen synthesis is normal (J:123605)
• glycogen synthesis is normal (J:123605)
• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)
• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)
• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)
• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)
• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)
• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)
• lower fasting glucose levels (J:56081)
• lower fasting glucose levels (J:56081)
• decrease in glycogen levels in the heart (J:83611)
• decrease in glycogen levels in the heart (J:83611)
• plasma levels are 2 fold higher than for controls, even when fasted (J:126461)
• increased leptin mRNA in adipocytes (J:126461)
• leptin response to intragastric glucose administration is strongly enhanced and persists at least 4 hours (J:126461)
• plasma levels are 2 fold higher than for controls, even when fasted (J:126461)
• increased leptin mRNA in adipocytes (J:126461)
• leptin response to intragastric glucose administration is strongly enhanced and persists at least 4 hours (J:126461)
• blood levels are decreased (J:126461)
• blood levels are decreased (J:126461)
• the uptake of oleate, a long chain fatty acid, by adipoctyes is reduced at low fatty acid:BSA ratios, indicating the absence of high affinity uptake in these cells (J:56081)
• adipocytes exhibit an increased incorporation of palmitate into diacylglycerol (J:56081)
• elicited peritoneal macrophages exhibit a 40-47% decrease in binding of oxidized LDL at saturation and a 63% decrease in cell association (J:56081)
• the uptake of oleate, a long chain fatty acid, by adipoctyes is reduced at low fatty acid:BSA ratios, indicating the absence of high affinity uptake in these cells (J:56081)
• adipocytes exhibit an increased incorporation of palmitate into diacylglycerol (J:56081)
• elicited peritoneal macrophages exhibit a 40-47% decrease in binding of oxidized LDL at saturation and a 63% decrease in cell association (J:56081)
• 50% reduction in oleic acid uptake in the first third of the small intestine (J:123605)
• also reduced uptake in the middle third but not in the distal third (J:123605)
• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine (J:123605)
• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine (J:123605)
• 50% reduction in oleic acid uptake in the first third of the small intestine (J:123605)
• also reduced uptake in the middle third but not in the distal third (J:123605)
• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine (J:123605)
• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine (J:123605)
• more cholesterol retained in the intestinal lumen (J:123605)
• 50% reduction in cholesterol output to lymph (J:123605)
• cholesterol uptake in the first third of the small intestine is reduced more than 60% (J:123605)
• no defect in cholesterol uptake in the distal two-thirds of the small intestine (J:123605)
• more cholesterol retained in the intestinal lumen (J:123605)
• 50% reduction in cholesterol output to lymph (J:123605)
• cholesterol uptake in the first third of the small intestine is reduced more than 60% (J:123605)
• no defect in cholesterol uptake in the distal two-thirds of the small intestine (J:123605)
• plasma beta hydroxybutyrate levels are increased (J:126461)
• plasma beta hydroxybutyrate levels are increased (J:126461)
• high density lipoprotein (HDL) particles are larger and contain increased phospholipid (J:56081)
• high density lipoprotein (HDL) particles are larger and contain increased phospholipid (J:56081)
• higher fasting and nonfasting levels of cholesterol (J:56081)
• higher fasting and nonfasting levels of cholesterol (J:56081)
• increase in cholesterol level is mainly due to an increase in the HDL fraction (J:56081)
• increase in cholesterol level is mainly due to an increase in the HDL fraction (J:56081)
• higher fasting levels of nonesterified free fatty acids (J:56081)
• higher fasting levels of nonesterified free fatty acids (J:56081)
• reduced incorporation of glucose into triglycerides (J:123605)
• reduced incorporation of glucose into triglycerides (J:123605)
• higher fasting levels of triacylglycerol, mainly within the very low density lipoprotein fraction (J:56081)
• higher fasting levels of triacylglycerol, mainly within the very low density lipoprotein fraction (J:56081)
• decrease in triglyceride levels in the heart (J:83611)
• decrease in triglyceride levels in the heart (J:83611)
• unadjusted metabolic rate is reduced by 15% (J:126461)
• rate adjusted to body weight is normal (J:126461)
• unadjusted metabolic rate is reduced by 15% (J:126461)
• rate adjusted to body weight is normal (J:126461)

cardiovascular system
• increase in the heart/body weight ratio, although exhibit no significant differences in body and heart weights (J:83611)
• increase in the heart/body weight ratio, although exhibit no significant differences in body and heart weights (J:83611)
• heart exhibits a significant decrease in palmitate oxidation and ATP levels, however cardiac output and end-diastolic pressure is normal under nonischemic conditions (J:83611)
• heart exhibits a significant decrease in palmitate oxidation and ATP levels, however cardiac output and end-diastolic pressure is normal under nonischemic conditions (J:83611)
• lower palmitate oxidation rates relative to controls offset by increased glucose oxidation levels with normal ATP production in another study (J:112746)
• cardiac work in non-ischemic hearts elevated relative to controls in another study (J:112746)
• lower palmitate oxidation rates relative to controls offset by increased glucose oxidation levels with normal ATP production in another study (J:112746)
• cardiac work in non-ischemic hearts elevated relative to controls in another study (J:112746)
• increase in glucose uptake in the heart (J:83611)
• increase in glucose uptake in the heart (J:83611)
• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)
• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)
• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)
• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)
• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)
• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)

muscle
• increase in glucose uptake in the heart (J:83611)
• increase in glucose uptake in the heart (J:83611)

growth/size/body
• total body fat about 38% lower than in controls (J:126461)
• lean mass normal (J:126461)
• total body fat about 38% lower than in controls (J:126461)
• lean mass normal (J:126461)
• body size smaller than in controls (J:123605)
• body size smaller than in controls (J:123605)
• weight difference from controls significant after 12 weeks of age (J:126461)
• weight difference from controls significant after 12 weeks of age (J:126461)
• gain less weight than controls (J:126461)
• weight difference from controls significant after 12 weeks of age (J:126461)
• gain less weight than controls (J:126461)
• weight difference from controls significant after 12 weeks of age (J:126461)

digestive/alimentary system
• small intestine is longer than in controls (J:123605)
• small intestine is longer than in controls (J:123605)
• increased glucose uptake rate in the first third of the small intestine (J:123605)
• increased glucose uptake rate in the first third of the small intestine (J:123605)
• 50% reduction in oleic acid uptake in the first third of the small intestine (J:123605)
• also reduced uptake in the middle third but not in the distal third (J:123605)
• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine (J:123605)
• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine (J:123605)
• 50% reduction in oleic acid uptake in the first third of the small intestine (J:123605)
• also reduced uptake in the middle third but not in the distal third (J:123605)
• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine (J:123605)
• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine (J:123605)
• more cholesterol retained in the intestinal lumen (J:123605)
• 50% reduction in cholesterol output to lymph (J:123605)
• cholesterol uptake in the first third of the small intestine is reduced more than 60% (J:123605)
• no defect in cholesterol uptake in the distal two-thirds of the small intestine (J:123605)
• more cholesterol retained in the intestinal lumen (J:123605)
• 50% reduction in cholesterol output to lymph (J:123605)
• cholesterol uptake in the first third of the small intestine is reduced more than 60% (J:123605)
• no defect in cholesterol uptake in the distal two-thirds of the small intestine (J:123605)

adipose tissue
• total body fat about 38% lower than in controls (J:126461)
• lean mass normal (J:126461)
• total body fat about 38% lower than in controls (J:126461)
• lean mass normal (J:126461)
• epididymal fat pads weigh less than in controls (J:126461)
• epididymal fat pads weigh less than in controls (J:126461)

skeleton
• significantly reduced bone mass (J:126461)
• significantly reduced bone mass (J:126461)

behavior/neurological
• food intake reduced 20% (J:126461)
• food intake reduced 20% (J:126461)

cellular
• increase in glucose uptake in the heart (J:83611)
• increase in glucose uptake in the heart (J:83611)

Mouse Models of Human Disease
OMIM ID Ref(s)
Platelet Glycoprotein IV Deficiency 608404 J:56081


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory